Skip to main content
Top
Published in: Cancer Microenvironment 1/2011

Open Access 01-04-2011 | Original Paper

Kinetics of Host Cell Recruitment During Dissemination of Diffuse Malignant Peritoneal Mesothelioma

Authors: Nathan R. Miselis, Bonnie W. Lau, Zhijin Wu, Agnes B. Kane

Published in: Cancer Microenvironment | Issue 1/2011

Login to get access

Abstract

Diffuse malignant mesothelioma is an aggressive tumor which displays a median survival of 11.2 months and a 5-year survival of less than 5% emphasizing the need for more effective treatments. This study uses an orthotopic model of malignant mesothelioma established in syngeneic, immunocompetent C57Bl/6 mice which produce malignant ascites and solid tumors that accurately replicate the histopathology of the human disease. Host stromal and immune cell accumulation within malignant ascites and solid tumors was determined using immunofluorescent labeling with confocal microscopy and fluorescence-activated cell sorting. An expression profile of cytokines and chemokines was produced using quantitative real-time PCR arrays. Tumor spheroids and solid tumors show progressive growth and infiltration with host stromal and immune cells including macrophages, endothelial cells, CD4+ and CD8+ lymphocytes, and a novel cell type, myeloid derived suppressor cells (MDSCs). The kinetics of host cell accumulation and inflammatory mediator expression within the tumor ascites divides tumor progression into two distinct phases. The first phase is characterized by progressive macrophage and T lymphocyte recruitment, with a cytokine profile consistent with regulatory T lymphocytes differentiation and suppression of T cell function. The second phase is characterized by decreased expression of macrophage chemotactic and T-cell regulating factors, an increase in MDSCs, and increased expression of several cytokines which stimulate differentiation of MDSCs. This cellular and expression profile suggests a mechanism by which host immune cells promote diffuse malignant mesothelioma progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mallory TB, Castleman B, Parris EE (1947) Case reports of the Massachussetts general hospital #33111. N Engl J Med 236:407–412CrossRef Mallory TB, Castleman B, Parris EE (1947) Case reports of the Massachussetts general hospital #33111. N Engl J Med 236:407–412CrossRef
2.
go back to reference Weldler HW (1943) Uber den Lugenhrebs bei asbestose. Dtsch Arch Klin Med 191:189–209 Weldler HW (1943) Uber den Lugenhrebs bei asbestose. Dtsch Arch Klin Med 191:189–209
3.
go back to reference Marinaccio A, Branchi C, Massari S et al (2006) National epidemiologic surveillance systems of asbestos-related disease and the exposed workers register. Med Lav 97:482–7PubMed Marinaccio A, Branchi C, Massari S et al (2006) National epidemiologic surveillance systems of asbestos-related disease and the exposed workers register. Med Lav 97:482–7PubMed
4.
go back to reference Roggli VL, Oury TD, Sporn TA (2004) Pathology of asbestos-associated diseases. Springer, New YorkCrossRef Roggli VL, Oury TD, Sporn TA (2004) Pathology of asbestos-associated diseases. Springer, New YorkCrossRef
5.
go back to reference Nowak AK, Byrne MJ, Williamson R et al (2002) A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87:491–6PubMedCrossRef Nowak AK, Byrne MJ, Williamson R et al (2002) A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87:491–6PubMedCrossRef
6.
go back to reference Lee TT, Everett DL, Shu HK et al (2002) Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 124:1183–9PubMedCrossRef Lee TT, Everett DL, Shu HK et al (2002) Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 124:1183–9PubMedCrossRef
7.
go back to reference Rusch VW (1997) Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9:367–72PubMed Rusch VW (1997) Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9:367–72PubMed
8.
go back to reference Pass HI, Kranda K, Temeck BK et al (1997) Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4:215–22PubMedCrossRef Pass HI, Kranda K, Temeck BK et al (1997) Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4:215–22PubMedCrossRef
9.
go back to reference Li Q, Yano S, Ogino H et al (2007) The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 13:5918–25PubMedCrossRef Li Q, Yano S, Ogino H et al (2007) The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 13:5918–25PubMedCrossRef
10.
go back to reference Broomfield S, Currie A, van der Most RG et al (2005) Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 65:7580–4PubMed Broomfield S, Currie A, van der Most RG et al (2005) Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 65:7580–4PubMed
11.
go back to reference Nowak AK, Robinson BW, Lake RA (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63:4490–6PubMed Nowak AK, Robinson BW, Lake RA (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63:4490–6PubMed
12.
go back to reference Lucchi M, Chella A, Melfi F et al (2007) A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 31:529–33, discussion 533-4PubMedCrossRef Lucchi M, Chella A, Melfi F et al (2007) A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 31:529–33, discussion 533-4PubMedCrossRef
13.
go back to reference Li H, Fan X, Houghton J (2007) Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 101:805–15PubMedCrossRef Li H, Fan X, Houghton J (2007) Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 101:805–15PubMedCrossRef
14.
go back to reference Miselis NR, Wu ZJ, Van Rooijen N et al (2008) Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7:788–99PubMedCrossRef Miselis NR, Wu ZJ, Van Rooijen N et al (2008) Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7:788–99PubMedCrossRef
15.
go back to reference Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254–65PubMedCrossRef Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254–65PubMedCrossRef
16.
go back to reference Martarelli D, Catalano A, Procopio A et al (2006) Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer 6:130PubMedCrossRef Martarelli D, Catalano A, Procopio A et al (2006) Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer 6:130PubMedCrossRef
17.
go back to reference Hegmans JP, Hemmes A, Hammad H et al (2006) Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 27:1086–95PubMedCrossRef Hegmans JP, Hemmes A, Hammad H et al (2006) Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 27:1086–95PubMedCrossRef
18.
go back to reference Davidson B, Dong HP, Holth A et al (2007) Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. Am J Clin Pathol 127:752–9PubMedCrossRef Davidson B, Dong HP, Holth A et al (2007) Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. Am J Clin Pathol 127:752–9PubMedCrossRef
19.
go back to reference Cordier Kellerman L, Valeyrie L, Fernandez N et al (2003) Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. Cancer Gene Ther 10:481–90PubMedCrossRef Cordier Kellerman L, Valeyrie L, Fernandez N et al (2003) Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. Cancer Gene Ther 10:481–90PubMedCrossRef
22.
go back to reference Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139–47PubMedCrossRef Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139–47PubMedCrossRef
23.
go back to reference Strizzi L, Catalano A, Vianale G et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468–75PubMedCrossRef Strizzi L, Catalano A, Vianale G et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468–75PubMedCrossRef
24.
go back to reference Strizzi L, Vianale G, Catalano A et al (2001) Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 18:1093–8PubMed Strizzi L, Vianale G, Catalano A et al (2001) Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 18:1093–8PubMed
25.
go back to reference Harvey P, Clark IM, Jaurand MC et al (2000) Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83:1147–53PubMedCrossRef Harvey P, Clark IM, Jaurand MC et al (2000) Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83:1147–53PubMedCrossRef
26.
go back to reference Bielefeldt-Ohmann H, Marzo AL, Himbeck RP et al (1995) Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother 40:241–50PubMedCrossRef Bielefeldt-Ohmann H, Marzo AL, Himbeck RP et al (1995) Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother 40:241–50PubMedCrossRef
27.
go back to reference Adachi Y, Aoki C, Yoshio-Hoshino N et al (2006) Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 119:1303–11PubMedCrossRef Adachi Y, Aoki C, Yoshio-Hoshino N et al (2006) Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 119:1303–11PubMedCrossRef
28.
go back to reference Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP et al (1994) Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 11:29–44PubMedCrossRef Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP et al (1994) Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 11:29–44PubMedCrossRef
30.
go back to reference Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H (1995) The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 12:455–60PubMed Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H (1995) The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 12:455–60PubMed
31.
go back to reference Kim S, Buchlis G, Fridlender ZG et al (2008) Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 68:10247–56PubMedCrossRef Kim S, Buchlis G, Fridlender ZG et al (2008) Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 68:10247–56PubMedCrossRef
32.
go back to reference Hodgson JT, Darnton A (2000) The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 44:565–601PubMed Hodgson JT, Darnton A (2000) The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 44:565–601PubMed
33.
go back to reference Kane AB (1998) Animal Models of Malignant Mesothelioma. In: Rom WN (ed) Environmental and occupational medicine. Lippincott-Raven, Boston, pp 377–386 Kane AB (1998) Animal Models of Malignant Mesothelioma. In: Rom WN (ed) Environmental and occupational medicine. Lippincott-Raven, Boston, pp 377–386
34.
go back to reference Goodglick LA, Vaslet CA, Messier NJ et al (1997) Growth factor responses and protooncogene expression of murine mesothelial cell lines derived from asbestos-induced mesotheliomas. Toxicol Pathol 25:565–73PubMedCrossRef Goodglick LA, Vaslet CA, Messier NJ et al (1997) Growth factor responses and protooncogene expression of murine mesothelial cell lines derived from asbestos-induced mesotheliomas. Toxicol Pathol 25:565–73PubMedCrossRef
35.
go back to reference Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R (ed) Bioinformatics and computational biology solutions using R and Bioconductor. Springer Science + Business Media, New York, pp 397–420CrossRef Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R (ed) Bioinformatics and computational biology solutions using R and Bioconductor. Springer Science + Business Media, New York, pp 397–420CrossRef
36.
go back to reference Mohr S, Keith G, Galateau-Salle F et al (2004) Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10 K-microarray. Biochim Biophys Acta 1688:43–60PubMed Mohr S, Keith G, Galateau-Salle F et al (2004) Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10 K-microarray. Biochim Biophys Acta 1688:43–60PubMed
37.
go back to reference Okayasu R, Wu L, Hei TK (1999) Biological effects of naturally occurring and man-made fibres: in vitro cytotoxicity and mutagenesis in mammalian cells. Br J Cancer 79:1319–24PubMedCrossRef Okayasu R, Wu L, Hei TK (1999) Biological effects of naturally occurring and man-made fibres: in vitro cytotoxicity and mutagenesis in mammalian cells. Br J Cancer 79:1319–24PubMedCrossRef
38.
go back to reference Hashimoto K, Morishige K, Sawada K et al (2005) Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res 65:540–5PubMed Hashimoto K, Morishige K, Sawada K et al (2005) Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res 65:540–5PubMed
39.
go back to reference Cespedes MV, Espina C, Garcia-Cabezas MA et al (2007) Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 170:1077–85PubMedCrossRef Cespedes MV, Espina C, Garcia-Cabezas MA et al (2007) Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 170:1077–85PubMedCrossRef
40.
go back to reference Tao K, Fang M, Alroy J et al (2008) Imagable 4 T1 model for the study of late stage breast cancer. BMC Cancer 8:228PubMedCrossRef Tao K, Fang M, Alroy J et al (2008) Imagable 4 T1 model for the study of late stage breast cancer. BMC Cancer 8:228PubMedCrossRef
41.
go back to reference Almand B, Clark JI, Nikitina E et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–89PubMed Almand B, Clark JI, Nikitina E et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–89PubMed
42.
go back to reference Gabrilovich DI, Velders MP, Sotomayor EM et al (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398–406PubMed Gabrilovich DI, Velders MP, Sotomayor EM et al (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398–406PubMed
43.
go back to reference Suzuki E, Kapoor V, Jassar AS et al (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713–21PubMedCrossRef Suzuki E, Kapoor V, Jassar AS et al (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713–21PubMedCrossRef
44.
go back to reference Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–506PubMedCrossRef Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–506PubMedCrossRef
45.
go back to reference Sinha P, Clements VK, Bunt SK et al (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179:977–83PubMed Sinha P, Clements VK, Bunt SK et al (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179:977–83PubMed
46.
go back to reference Terabe M, Matsui S, Park JM et al (2003) Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198:1741–52PubMedCrossRef Terabe M, Matsui S, Park JM et al (2003) Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198:1741–52PubMedCrossRef
47.
go back to reference Cheadle EJ, Riyad K, Subar D et al (2007) Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res 13:5719–28PubMedCrossRef Cheadle EJ, Riyad K, Subar D et al (2007) Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res 13:5719–28PubMedCrossRef
48.
go back to reference Qin XJ, Shi HZ, Huang ZX et al (2005) Interleukin-16 in tuberculous and malignant pleural effusions. Eur Respir J 25:605–11PubMedCrossRef Qin XJ, Shi HZ, Huang ZX et al (2005) Interleukin-16 in tuberculous and malignant pleural effusions. Eur Respir J 25:605–11PubMedCrossRef
49.
go back to reference Lenz G, Wright G, Dave SS et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313–23PubMedCrossRef Lenz G, Wright G, Dave SS et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313–23PubMedCrossRef
50.
go back to reference Ancuta P, Wang J, Gabuzda D (2006) CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol 80:1156–64PubMedCrossRef Ancuta P, Wang J, Gabuzda D (2006) CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol 80:1156–64PubMedCrossRef
51.
go back to reference Hu Y, Ivashkiv LB (2006) Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. J Immunol 176:6022–33PubMed Hu Y, Ivashkiv LB (2006) Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. J Immunol 176:6022–33PubMed
52.
go back to reference Han IS, Ra JS, Kim MW et al (2003) Differentiation of CD34+ cells from human cord blood and murine bone marrow is suppressed by C6 beta-chemokines. Mol Cells 15:176–80PubMed Han IS, Ra JS, Kim MW et al (2003) Differentiation of CD34+ cells from human cord blood and murine bone marrow is suppressed by C6 beta-chemokines. Mol Cells 15:176–80PubMed
Metadata
Title
Kinetics of Host Cell Recruitment During Dissemination of Diffuse Malignant Peritoneal Mesothelioma
Authors
Nathan R. Miselis
Bonnie W. Lau
Zhijin Wu
Agnes B. Kane
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1/2011
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-010-0048-1

Other articles of this Issue 1/2011

Cancer Microenvironment 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine